Prisys Biotechnologies Co., Ltd. is a leading biotech-CRO based in Shanghai, China. In addition to our superior Drug Efficacy & Safety services in Nonhuman Primates (NHP) and lower species, we are offering a novel translational research platform to the new drug R&D industry, with the following major features:
• An integrated platform combining preclinical research, medical sciences, animal experiment technologies, animal breeding etc., for the one-of-a-kind solution for drug efficacy & safety assessment.
• A rich library of novel NHP disease models, covering multiple fields such as immunology, metabolism, cardiovascular, respiratory, kidney, liver, neurology, ophthalmology, etc.,
• Advanced in vivo l imaging technologies, including PET/CT, MRI, DR, ultrasound, etc., with full capabilities of imaging sequences and analytical diagnosis
• Clinical equivalent surgical operation with integrated radio-intervention (digital subcontracting angiography, DSA) capability.
• Independent disease research department including technologies specialized for NHP pulmonary, cardiovascular, CNS-related, metabolic, infectious, ophthalmic diseases.
• High standard animal welfare enrichment programs and systemic innovation, including active IACUC+OHSP, constant 3R practices, luxury housing & rich enrichment options for experimental animals, etc.

Our track record of success in the past decade proved we are a reliable partner for drug translational R&D, during both preclinical & early-clinical stages. We have extensive experiences collaborating with oversea pharmaceutical and biotech researchers. Please don’t hesitate to contact us to learn more or get a cost-effective quotation for your study:

Email: jane.liu@ prisysbiotech.com
bd@prisysbiotech.com
Phone: +86-21-5043-5616
Website: www.prisysbiotech.com